Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infectionMORSE, G. D; FISCHL, M. A; SHELTON, M. J et al.Antimicrobial agents and chemotherapy. 1997, Vol 41, Num 1, pp 169-174, issn 0066-4804Article

Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failedBELLMAN, P. C.AIDS (London). 1998, Vol 12, Num 11, pp 1333-1340, issn 0269-9370Article

Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patientsSHELTON, Mark J; HEWITT, Ross G; ADAMS, John et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 5, pp 1694-1699, issn 0066-4804, 6 p.Article

Factor analysis of infrared spectra for solid-state forms of delavirdine mesylateSARVER, R. W; MEULMAN, P. A; BOWERMAN, D. K et al.International journal of pharmaceutics. 1998, Vol 167, Num 1-2, pp 105-120, issn 0378-5173Article

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected childrenWINTERGERST, U; ENGELHORN, C; KUROWSKI, M et al.AIDS (London). 2000, Vol 14, Num 12, pp 1866-1868, issn 0269-9370Article

Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrantROHRS, B. R; THAMANN, T. J; PING GAO et al.Pharmaceutical research. 1999, Vol 16, Num 12, pp 1850-1856, issn 0724-8741Article

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects : ACTG 884FLETCHER, Courtney V; ACOSTA, Edward P; GULICK, Roy M et al.AIDS (London). 2000, Vol 14, Num 16, pp 2495-2501, issn 0269-9370Article

Characterization of three crystalline forms (VIII, XI, and XII) and the amorphous form (V) of delavirdine mesylate using ¹³C CP/MAS NMRPING GAO.Pharmaceutical research. 1998, Vol 15, Num 9, pp 1425-1433, issn 0724-8741Article

Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in ratsCHANG, M; SOOD, V. K; WILSON, G. J et al.Drug metabolism and disposition. 1997, Vol 25, Num 2, pp 228-242, issn 0090-9556Article

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteersFERRY, J. J; HERMAN, B. D; CAREL, B. J et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1998, Vol 18, Num 3, pp 252-259, issn 1077-9450Article

Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptaseSILVESTRI, Romano; ARTICO, Marino; DE MARTINO, Gabriella et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 8, pp 1567-1576, issn 0022-2623Article

Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutantsEL-BROLLOSY, Nasser R; JØRGENSEN, Per T; DAHAN, Berit et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 26, pp 5721-5726, issn 0022-2623, 6 p.Article

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detectionVELDKAMP, A. I; VAN HEESWIJK, R. P. G; HOETELMANS, R. M. W et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 727, Num 1-2, pp 151-157, issn 1387-2273Article

Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3AVOORMAN, R. L; MAIO, S. M; HAUER, M. J et al.Drug metabolism and disposition. 1998, Vol 26, Num 7, pp 631-639, issn 0090-9556Article

Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two- and three-drug combinations of delavirdine, lamivudine and zidovudinePAGANO, P. J; CHONG, K. T.Antiviral chemistry & chemotherapy. 1997, Vol 8, Num 4, pp 333-341, issn 0956-3202Article

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteersJUSTESEN, Ulrik S; KLITGAARD, Niels A; BROSEN, Kim et al.British journal of clinical pharmacology. 2003, Vol 55, Num 1, pp 100-106, issn 0306-5251, 7 p.Article

Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIsRAWAL, R. K; MURUGESAN, V; KATTI, S. B et al.Current medicinal chemistry. 2012, Vol 19, Num 31, pp 5364-5380, issn 0929-8673, 17 p.Article

Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patientsBAKER, Jennifer R; BEST, Al M; PADE, Patricia A et al.The Annals of pharmacotherapy. 2006, Vol 40, Num 3, pp 392-396, issn 1060-0280, 5 p.Article

Delavirdine increases drug exposure of ritonavir-boosted protease inhibitorsHARRIS, Marianne; ALEXANDER, Chris; O'SHAUGHNESSY, Michael et al.AIDS (London). 2002, Vol 16, Num 5, pp 798-799, issn 0269-9370Article

Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasmaPROUST, V; TOTH, K; HULIN, A et al.Journal of chromatography. B, Biomedical sciences and applications. 2000, Vol 742, Num 2, pp 453-458, issn 1387-2273Article

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir : AIDS Clinical Trials Group Study 359GULICK, Roy M; HU, X. Joan; SNYDER, Sally et al.The Journal of infectious diseases. 2000, Vol 182, Num 5, pp 1375-1384, issn 0022-1899Article

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients : Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trialJOLY, Véronique; MORONI, Mauro; WILKINS, Edmund G. L et al.Antimicrobial agents and chemotherapy. 2000, Vol 44, Num 11, pp 3155-3157, issn 0066-4804Article

Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeysCHANG, M; SOOD, V. K; KLOOSTERMAN, D. A et al.Drug metabolism and disposition. 1997, Vol 25, Num 7, pp 814-827, issn 0090-9556Article

In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophagesBEEN-TIKTAK, A. M. M; DE HAAS, C. J. C; DE GRAAF, L et al.Journal of antimicrobial chemotherapy (Print). 1997, Vol 40, Num 6, pp 847-853, issn 0305-7453Article

Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their ToxicityBLAS-GARCIA, A; ESPLUGUES, J. V; APOSTOLOVA, N et al.Current medicinal chemistry. 2011, Vol 18, Num 14, pp 2186-2195, issn 0929-8673, 10 p.Article